Doer Biologics Announced Completes Enrollment of the Phase 2 Clinical Study of DR10624, reported by mainstream media

Recently,many mainstream media forwarded the "Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia" released by CISION PR on March 09, 2025, following are some news links:

AP NEWS、Market Watch、KTLA5、Seeking Alpha、PR Newswire